title: Antisense approaches to immune modulation for transplant and autoimmune diseases.
abstract: Antisense oligomers have been shown to be effective tools for inhibiting gene expression in a highly specific manner. This technology has proven to be invaluable for determining gene function in conventional molecular and cellular studies. However, the promise of an antisense-based drug technology, suggested by antiviral efficacy shown nearly 25 years ago, is just now coming of age. Since then, numerous antisense approaches have been shown to be effective in animal models against numerous viruses and some tumors. Not surprisingly, antisense agents targeting these diseases are taking the lead in human clinical trials and FDA approval. Although comparatively smaller in scope, approaches for modulating immune responses to treat Crohn's disease, diabetes, multiple sclerosis and transplant rejection appear to be the next burgeoning phase of development in antisense therapy.
authors.affiliation: Oregon State University Department of Microbiology, Nash Hall 220, Corvallis, OR 97333, USA. dmourich@avibio.com
authors.forename: Dan V
authors.initials: DV
authors.lastname: Mourich
authors.forename: Nikki B
authors.initials: NB
authors.lastname: Marshall
mesh_terms: D001327:Autoimmune Diseases / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology*; D006085:Graft Survival / Q000187:drug effects* / Q000235:genetics / Q000276:immunology*; D006801:Humans; D016376:Oligonucleotides, Antisense / Q000235:genetics / Q000494:pharmacology* / Q000627:therapeutic use*; D050378:T-Lymphocytes, Regulatory / Q000187:drug effects / Q000276:immunology / Q000378:metabolism
chemical_list: D016376:Oligonucleotides, Antisense